Search - tctmd.com

Displaying 81 - 100 of 111

Sort: Relevancy | Date

News Daily News

ESC Offers Recommendations on Use of New Oral Anticoagulants

Yael L. Maxwell

May 03, 2013

News Daily News

Danish Registry: Dabigatran Safe, Effective in Real-World Use

Caitlin E. Cox

April 05, 2013

News Daily News

Bleeding Score Helps Clinicians Target PCI Patients Best Suited for Bivalirudin

Caitlin E. Cox

March 09, 2013

News Daily News

Bivalirudin Shows Advantage Over GPIs—But Not Heparin Alone—in STEMI Patients

L.A. McKeown

November 28, 2012

News Conference News AHA 2012

Evidence Continues to Support Dabigatran Treatment in A-fib

November 06, 2012

News Daily News

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Jason Kahn

October 19, 2012

News Daily News

In Transradial PCI, Bivalirudin Fails to Budge Event Rates vs. Heparin

October 12, 2012

News Daily News

Dabigatran Usage up, Both for A-fib and Off-Label Indications

September 12, 2012

News Conference News ESC 2012

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

August 26, 2012

News Daily News

Indirect Comparisons Show Little Difference Among New Anticoagulants

August 14, 2012

News Daily News

IABP Use Most Risky in ACS Patients Undergoing Urgent PCI

March 22, 2012

News Daily News

Registry Confirms Bivalirudin Better for STEMI in ‘Real World’

March 07, 2012

News Daily News

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

L.A. McKeown

January 09, 2012

News Conference News

ISAR-REACT 4: Bivalirudin Reduces Major Bleeding in NSTEMI Patients

November 13, 2011

News Daily News

Meta-analysis: Intracoronary vs. IV Abciximab Improves Survival in STEMI Patients

L.A. McKeown

November 01, 2011

News Daily News

Bivalirudin Decreases Bleeding Regardless of Heparin Anticoagulation Level

Yael L. Maxwell

October 13, 2011

News Daily News

Hope Renewed for Novel Anticoagulant Use in ACS

Caitlin E. Cox

October 05, 2011

News Daily News

HORIZONS-AMI: CKD Patients Fare Poorly Regardless of Stent Type, Antithrombotic Regimen

Leah Lawrence

September 29, 2011

News Daily News

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

L.A. McKeown

September 13, 2011

News Conference News

ESC Congress 2011: Drugs, Devices Work Together

Caitlin E. Cox

September 06, 2011

Advertisement

ESC Offers Recommendations on Use of New Oral Anticoagulants

Danish Registry: Dabigatran Safe, Effective in Real-World Use

Bleeding Score Helps Clinicians Target PCI Patients Best Suited for Bivalirudin

Bivalirudin Shows Advantage Over GPIs—But Not Heparin Alone—in STEMI Patients

Evidence Continues to Support Dabigatran Treatment in A-fib

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

In Transradial PCI, Bivalirudin Fails to Budge Event Rates vs. Heparin

Dabigatran Usage up, Both for A-fib and Off-Label Indications

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

Indirect Comparisons Show Little Difference Among New Anticoagulants

IABP Use Most Risky in ACS Patients Undergoing Urgent PCI

Registry Confirms Bivalirudin Better for STEMI in ‘Real World’

Meta-Analysis Shows Increased Risk of MI, ACS with Dabigatran

ISAR-REACT 4: Bivalirudin Reduces Major Bleeding in NSTEMI Patients

Meta-analysis: Intracoronary vs. IV Abciximab Improves Survival in STEMI Patients

Bivalirudin Decreases Bleeding Regardless of Heparin Anticoagulation Level

Hope Renewed for Novel Anticoagulant Use in ACS

HORIZONS-AMI: CKD Patients Fare Poorly Regardless of Stent Type, Antithrombotic Regimen

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

ESC Congress 2011: Drugs, Devices Work Together

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content